摘要
目的:观察原发性高血压患者应用血管紧张素转换酶抑制剂(ACEI)酰托普利(Ceptopril)治疗前后血浆单核细胞趋化蛋白-1(MCP-1)浓度、MCP-1信使核糖核酸(mRNA)表达及血压的变化,初步探讨MCP-1与高血压的可能关系。方法:选择轻、中度原发性高血压患者60例,随机分入酰托普利组(n=30)和双氢克尿噻组(n=30),分别予酰托普利和双氢克尿噻治疗8周。测定了治疗前后的血压、MCP-1浓度以及外周血单个核细胞MCP-1的mRNA表达水平。另选30例健康人为正常对照组。结果:与正常对照组相比,高血压患者血浆MCP-1浓度及单个核细胞MCP-1的mRNA表达明显升高;酰托普利组治疗后,血压明显降低同时血浆MCP-1浓度及其mRNA表达也明显下降;双氢克尿噻组虽降压效果与酰托普利组类似,但无相应的MCP-1变化。结论:MCP-1是影响高血压患者血压的因素之一,酰托普利除有效降压外还可通过降低炎症因子MCP-1的表达使患者获益。
Objective: To observe the effect of angiotensin-converting enzyme inhibitor( ACEI) ceptopril on the concentration of plasma monocyte chemoattractant protein-1 ( MCP-1) , the expression of MCP-1 mRNA and blood pressure in patients with essential hypertension, and to explore the possible relationship between MCP-1 and blood pressure. Methods: In this trial, we recruited 60 patients with mild to moderate essential hypertension who were randomized to receive ceptopril 15-30mg or hydrodiuril for 8 weeks. Blood pressure, plasma level of MCP-1 and mRNA expression of MCP-1 were compared before and after treatment; the former two were detected by radioimmunoassay (RIA ) and enzyme linked immunosor-bentassay (ELISA) , separately, the later by reverse transcriptase polymerase chain reaction (RT-PCR). Results: The plasma level of MCP-1 and the gene expression of MCP-1 in hypertensive patients before treatment were significantly higher than of normotensive controls. MCP-1 was closely related to blood pressure. The anti-hypertensive evenness rate of ceptopril was 96%. Cough developed in 3% of ceptopril group. Although hydrodiuril had the same antihypertensive effect as that of ceptopril, yet it brought about no change in MCP-1. Conclusion: MCP-1 is one of the factors having effect on blood pressure. In addition to lowering blood pressure, ceptopril can benefit the patients by reduction of inflammation factor MCP-1.
出处
《中国循环杂志》
CSCD
北大核心
2005年第2期130-133,共4页
Chinese Circulation Journal
